A Phase 1 interventional study of Tacrolimus single dose and Epidiolex single dose in CBD, Transplant Complication and Kidney Disease, Chronic, sponsored by Indiana University. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Indiana University · Phase 1, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Renal Insufficiency, Chronic by Indiana University — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency, Chronic · Indiana University.
Among the 12 studies in Renal Insufficiency, Chronic by Indiana University, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 1, and was the 10th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →2 of the 12 studies in Renal Insufficiency, Chronic by Indiana University are open now, in 12 countries. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 40–70
Indiana University · Sites in United States, Argentina, Australia and 30 more countries
Ages 0 min–2 wk
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 37 across the 10 interventional studies, 4,036 across the 2 observational. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
1 of the studies in Renal Insufficiency, Chronic by Indiana University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Renal Insufficiency, Chronic by Indiana University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant recipients.
The commercial availability of cannabidiol, or CBD oil, has increased in the United Stated and this supplement has the potential to cause a variety of drug-drug interactions, including in solid organ transplant recipients who receive tacrolimus to prevent rejection. Through a series of pharmacokinetic and pharmacodynamics assays, this proposal will identify gene-drug and drug-drug interactions (DDI), including those that place transplant recipients at risk for increased toxicity related to their immunosuppression. The information learned in these studies will help to inform practitioners as to whether cannabidiol needs to be avoided in transplant recipients and how to appropriately adjust doses of CBD and immunosuppression in order to improve health outcomes and long-term treatment success in this high-risk population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Criteria for the Healthy volunteer study:
Additional Criteria for the CKD study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tacrolimus single dose · Drug: Epidiolex single dose · Drug: Epidiolex steady-state and tacrolimus single dose
Drug: Tacrolimus single dose · Drug: Epidiolex single dose · Drug: Epidiolex steady-state and tacrolimus single dose
Drug: Tacrolimus single dose · Drug: Epidiolex single dose · Drug: Epidiolex steady-state and tacrolimus single dose
Drug: Tacrolimus single dose · Drug: Epidiolex single dose · Drug: Epidiolex steady-state and tacrolimus single dose
5 mg once
Also known as: Period 1
Epidiolex 5 mg/kg
Also known as: Period 2
Drug page: PNU-100480Studies of PNU-100480PNU-100480 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
Also known as: Period 3
The AUC0-Infinity Ratio of Tacrolimus With Cannabidiol Divided by Tacrolimus Alone
The primary outcome is the AUC0-Infinity ratio of tacrolimus with cannabidiol divided by tacrolimus alone between CYP3A5 expressers and non-expressers in subjects with and without chronic kidney disease (CKD). Tacrolimus whole blood concentrations were measured at 0, 20, 40, and 60 minutes and 2, 4, 6, 12, 24, 48, and/or 72 hours.
Time frame: 27 days
Cell Viability Ratio
The hypothesis tested is that cannabidiol will reduce immune cell proliferation between Period 1 and Period 3. There is no comparison between CYP3A5 expressor groups intended for this outcome measure. Period 1 (pre-CBD or baseline measurement) and Period 3 (post-CBD or steady-state cannabidiol) will be compared in a subset of individuals undergoing this phenotyping. Cell viability was measured in peripheral blood mononuclear cells using CellTiter-Glo (Promega Corp., catalog G7570) on 96-well plates to quantify cell proliferation by adenosine triphosphate (ATP) detection using a Spectramax M5 system coupled with SoftMax Pro 5.2 (Molecular Devices). Values were calculated as a unitless ratio of luminescence (ATP detection) in the stimulated (CD3/CD28) condition normalized by the non-stimulated (No CD3/CD28) condition.
Time frame: 27 days
We will recruit a mix of individuals with and without CKD because this is representative of the transplant population. We will also recruit a mix of CYP3A5 expressors and non-expressors. Patients who have given consent to be recontacted in prior studies or as part of the Indiana Biobank will be called or sent a letter for recruitment. Advertising and recruiting outside of these already genotyped pools of subjects will also be done. Our main recruitment site is the Indiana University campus.
| Milestone | CYP3A5 Expressers Without Chronic Kidney Disease | CYP3A5 Expressers With Chronic Kidney Disease | CYP3A5 Non-expressers Without Chronic Kidney Disease | CYP3A5 Non-expressers With Chronic Kidney Disease | Non-Genotyped |
|---|---|---|---|---|---|
| Started | 10 | 4 | 23 | 7 | 13 |
| Completed | 10 | 4 | 20 | 7 | 0 |
| Not completed | 0 | 0 | 3 | 0 | 13 |
The primary outcome is the AUC0-Infinity ratio of tacrolimus with cannabidiol divided by tacrolimus alone between CYP3A5 expressers and non-expressers in subjects with and without chronic kidney disease (CKD). Tacrolimus whole blood concentrations were measured at 0, 20, 40, and 60 minutes and 2, 4, 6, 12, 24, 48, and/or 72 hours.
| AUC0-Infinity Ratio | CYP3A5 Non-expressers Without Chronic Kidney Disease (Who Completed the Study in Its Entirety) | CYP3A5 Expressers Without Chronic Kidney Disease (Who Completed the Study in Its Entirety) | CYP3A5 Non-expressers With Chronic Kidney Disease (Who Completed the Study in Its Entirety) | CYP3A5 Expressers With Chronic Kidney Disease (Who Completed the Study in Its Entirety) |
|---|---|---|---|---|
| The AUC0-Infinity Ratio of Tacrolimus With Cannabidiol Divided by Tacrolimus Alone | 2.9 (2.6 to 3.1) | 3.8 (3.1 to 4.7) | 2.5 (2.0 to 3.0) | 2.4 (0.8 to 6.7) |
The hypothesis tested is that cannabidiol will reduce immune cell proliferation between Period 1 and Period 3. There is no comparison between CYP3A5 expressor groups intended for this outcome measure. Period 1 (pre-CBD or baseline measurement) and Period 3 (post-CBD or steady-state cannabidiol) will be compared in a subset of individuals undergoing this phenotyping. Cell viability was measured in peripheral blood mononuclear cells using CellTiter-Glo (Promega Corp., catalog G7570) on 96-well plates to quantify cell proliferation by adenosine triphosphate (ATP) detection using a Spectramax M5 system coupled with SoftMax Pro 5.2 (Molecular Devices). Values were calculated as a unitless ratio of luminescence (ATP detection) in the stimulated (CD3/CD28) condition normalized by the non-stimulated (No CD3/CD28) condition.
| luminescence/luminescence | Period 1 | Period 3 |
|---|---|---|
| Cell Viability Ratio | 2.04 ± 0.574 | 1.5 ± 0.571 |
Collected over from enrollment/consent until end of follow-up (approximately 28 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CYP3A5 Expressers Without Chronic Kidney Disease | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| CYP3A5 Non-expressers Without Chronic Kidney Disease | 0/23 (0%) | 0/23 (0%) | 21/23 (91.3%) |
| CYP3A5 Expressers With Chronic Kidney Disease | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| CYP3A5 Non-expressers With Chronic Kidney Disease | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Non-Genotyped | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Event | CYP3A5 Expressers Without Chronic Kidney Disease | CYP3A5 Non-expressers Without Chronic Kidney Disease | CYP3A5 Expressers With Chronic Kidney Disease | CYP3A5 Non-expressers With Chronic Kidney Disease | Non-Genotyped |
|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/10 | 19/23 | 1/4 | 4/7 | 0/13 |
| DiarrheaGastrointestinal disorders | 6/10 | 19/23 | 2/4 | 4/7 | 0/13 |
| Sleepiness/FatigueNervous system disorders | 7/10 | 13/23 | 3/4 | 5/7 | 0/13 |
| Poor SleepNervous system disorders | 3/10 | 9/23 | 2/4 | 4/7 | 0/13 |
| Decreased AppetiteGastrointestinal disorders | 5/10 | 7/23 | 0/4 | 2/7 | 0/13 |
| RashSkin and subcutaneous tissue disorders | 0/10 | 5/23 | 2/4 | 0/7 | 0/13 |
| HeadacheNervous system disorders | 3/10 | 2/23 | 0/4 | 2/7 | 0/13 |
| LethargicNervous system disorders | 0/10 | 0/23 | 1/4 | 0/7 | 0/13 |
| NightmaresNervous system disorders | 0/10 | 0/23 | 1/4 | 1/7 | 0/13 |
| LightheadedNervous system disorders | 0/10 | 0/23 | 1/4 | 0/7 | 0/13 |
Consented patients counted, some participants may have been excluded after the screening process due to failing some aspect of the required tests done (for example: failed urine drug screen or high BMI). Participants may have also chosen to exclude themselves after screening for various reasons (for example: lack of time to attend study visits)
| Age, Continuous(Years) | CYP3A5 Expressers Without Chronic Kidney Disease | CYP3A5 Expressers With Chronic Kidney Disease | CYP3A5 Non-expressers Without Chronic Kidney Disease | CYP3A5 Non-expressers With Chronic Kidney Disease | Non-Genotyped | Total |
|---|---|---|---|---|---|---|
| Mean | 41.30 ± 19.56 | 66.75 ± 18.22 | 38.65 ± 10.95 | 63.71 ± 14.68 | 52.69 ± 9.13 | 47.37 ± 16.61 |
| Sex: Female, Male(Participants) | CYP3A5 Expressers Without Chronic Kidney Disease | CYP3A5 Expressers With Chronic Kidney Disease | CYP3A5 Non-expressers Without Chronic Kidney Disease | CYP3A5 Non-expressers With Chronic Kidney Disease | Non-Genotyped | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 3 | 18 | 6 | 9 | 41 |
| Male | 5 | 1 | 5 | 1 | 4 | 16 |
| Race (NIH/OMB)(Participants) | CYP3A5 Expressers Without Chronic Kidney Disease | CYP3A5 Expressers With Chronic Kidney Disease | CYP3A5 Non-expressers Without Chronic Kidney Disease | CYP3A5 Non-expressers With Chronic Kidney Disease | Non-Genotyped | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 2 | 0 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 4 | 4 | 2 | 9 | 27 |
| White | 1 | 0 | 17 | 5 | 3 | 26 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | CYP3A5 Expressers Without Chronic Kidney Disease | CYP3A5 Expressers With Chronic Kidney Disease | CYP3A5 Non-expressers Without Chronic Kidney Disease | CYP3A5 Non-expressers With Chronic Kidney Disease | Non-Genotyped | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 9 | 4 | 23 | 7 | 13 | 56 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Aug 2025, 34 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 109 phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 34 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PNU-100480
Renal Insufficiency, Chronic →